Michelle Kim-Danely

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Breakout Labs
Portfolio Manager 

Marnin Kligfeld

Makena Partners LP

Richard Koffler

Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.

Websites:
www.greenwingsbiomedical.com
techcoastangels.com

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Tech Coast Angels
Member 

Bill Kohlbrenner

Boston Innovation Capital

Garheng Kong United States

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Garheng Kong
HealthQuest Capital
Managing Partner 
Mr Andrew Koopman
New York University
LinkedIn logo Director New Ventures 
BIO

Andrew Koopman works with investors and entrepreneurs to facilitate the formation of new life science companies that focus on the development and commercialization of NYU technologie, as well as working with these companies to obtain the capital and human resources for growth. In addition to more than a decade in academic technology transfer, Andrew has 16 years of varied experience in the biotechnology industry. He has held scientist, laboratory supervisor, and project manager positions in the course of his employment at two successful biotechnology startup companies, as well as Johnson & Johnson and Hoffman-LaRoche. During this period he was involved in the development of several therapeutic and diagnostic products which are currently on the market.  Prior to joining the NYU Office of Industrial Liaison, Andrew was the Managing Director of Biomedical and Biotechnology Industries at Beroff Associates, a merchant investment banking and strategic advisory group. He has also provided consulting to a number of startup companies, investment groups, and public agencies regarding technology assessment, market analysis, business development, and financing strategies. Andrew is an active board member and advisor of Zero Gravity Solutions, Inc. (Pink Sheets: ZGSI) and Applied Glycan, LLC.     

Mike Kope United States

SENS Research Foundation is based in Mountain View, CA. The foundation provides grants for research into rejuvenation biotechnologies that prevent or reverse age-related tissue damage. Historically grants have ranged from $40,000 to $200,000 although this range may change in the future. Grants are available to researchers worldwide. SENS requests that grants not be used to cover overhead/facilities costs. At present, 15 projects are being supported.

SENS Research Foundation, Inc.
CEO and President 

Ronnie Koss United States

Year Founded
2008
Service Provider Type
Unique Capabilities

Scout. Evaluate. Invest. Manage.

ideaPoint delivers the leading innovation management solution for the global enterprise. With ideaPoint software, you can scout, evaluate, invest in, track and manage dynamic growth opportunities – all with one secure, simple tool.

ideaPoint provides full lifecycle management of BD/Licensing and acquisition opportunities from scouting, to evaluation, to negotiation, to alliance management; while offering robust tracking and reporting capabilities. Clients include some of the world's most successful BioScience companies.


ideaPoint brings to the enterprise a comprehensive toolset and our best practices to help companies better collaborate and partner in a secure virtual environment.

With ideaPoint software, companies can tactically scout, evaluate and seize a range of growth opportunities, secure strategic partnerships, and manage critical requests, initiatives and alliances

Our solution delivers visibility and facilitates collaboration across an organization and with external partners, streamlining the flow of complex information and optimizing the unique process of each team.

With virtual team assembly and automated routing, robust tracking and on-demand reporting, the ideaPoint solution reduces administrative overhead, increases efficiency and efficacy of process, and provides a simple and intuitive user experience.

ideaPoint
VP - Development 

Kate Kraft

Cote Orphan, LLC
Business Development & Strategic Partnering 

Kelly Krajnik

Mayo Clinic Ventures serves to commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic. The office has licensed hundreds of technologies in the fields of medical devices, diagnostics, therapeutics, and healthcare IT, and has focused efforts in technology-based ventures and start-ups.  Mayo Clinic Ventures also has a $20M venture capital fund which is used to spin out companies that are developing products based on Mayo Clinic research.

Mayo Clinic Ventures
Business Development Manager